Are there any ongoing clinical trials that could affect lurbinectedin's approval?

Short answer: Yes—there are ongoing trials with lurbinectedin that could influence its regulatory status, including confirmatory trials and studies evaluating new indications or combinations. However, I don’t have real-time trial data here.

What could affect approval
- Confirmatory studies: If a ongoing or upcoming Phase 3 trial confirms a meaningful benefit with acceptable safety, the label could be expanded or the therapy could gain stronger regulatory support.
- Label restrictions or withdrawal: If ongoing trials raise safety concerns or fail to demonstrate benefit, regulators could restrict the label, require warning changes, or in rare cases withdraw approval.
- New indications/combinations: Positive results in first-line SCLC, other chemo-sensitive cancers, or in combination with immunotherapies could expand the drug’s approved uses.
- Safety signals: New adverse events or worse-than-expected tolerability in ongoing trials could influence labeling.

How you can check the latest status
- ClinicalTrials.gov: Search for “lurbinectedin” or “PM01183” to see ongoing trials, their phases, locations, recruitment status, and endpoints.
- Company sources: Look for press releases or investor updates from PharmaMar (the developer) and Jazz Pharmaceuticals (which has been involved in rights and commercialization in some regions).
- Regulatory updates: FDA announcements or EMA communications can signal changes to labeling or approval status.
- Reviews/publications: Periodic reviews in oncologic conferences or journals may summarize interim results that could influence regulatory views.

If you’d like, I can look up the current list of active trials and summarize their statuses and endpoints. Just say “Yes, search,” and I’ll pull the latest figures and highlight which trials are most likely to impact approval. Note: I can’t browse in real time unless you want me to fetch current data; I’ll also clearly indicate the date of any information I provide.